PurMinds Enterprises, Inc., formerly Pacific Software, Inc., is a precision neuro-medicine development company pursuing solutions to neurological and psychiatric disorders. The Company's clinical pipeline includes neuroprotective compounds that restore neuronal functions and can address multiple clinical indications with significant unmet patient needs. The Company is focused on a 4P Medicine platform, in strategic partnership with SpectroChip Global Inc., for early detection and intervention of conditions before irreversible damage occurs. The Company operates under a Health Canada issued Controlled Drugs and Substances License. It has developed a pipeline of proprietary formulations and novel small molecules (NCEs). The Company's pipeline includes PUR100 Series and PUR500 Series.

Employees

Sector

Biotechnology & Medical Research

More about the company

06-10	Purminds Enterprises, Inc. Announces CFO Changes	CI
06-10	PurMinds Enterprises, Inc. Announces Appointment of Angelo Pizzuto as Chief Operating Officer, Secretary, and Treasurer, Effective June 10, 2026	CI

Market Cap	48.82M 41.99M 39.62M 36.09M 67.46M 4.67B 68.08M 472M 182M 2.37B 183M 179M 7.52B	P/E 2019	-2.65x	P/E 2020	-41.2x
Enterprise Value	49.19M 42.3M 39.91M 36.36M 67.97M 4.7B 68.59M 475M 183M 2.39B 185M 181M 7.58B	EV / Sales 2019	-	EV / Sales 2020	2,435,972,350x
Free-Float	64%	Yield 2019 *	-	Yield 2020	-

06-10	Purminds Enterprises, Inc. Announces CFO Changes	CI
06-10	PurMinds Enterprises, Inc. Announces Appointment of Angelo Pizzuto as Chief Operating Officer, Secretary, and Treasurer, Effective June 10, 2026	CI
11-11	Pacific Software Inc Announces Exclusive Partnership with SpectroChip Global Inc	CI
11-11	Pacific Software, Inc. acquired 10763942 Canada Inc. and PurMinds Asset Portfolio from PurMinds NeuroPharma Inc.	CI
26/08/25	Pacific Software, Inc. agreed to acquire 10763942 Canada Inc. and PurMinds Asset Portfolio from PurMinds NeuroPharma Inc.	CI
23/07/24	Robert Schiestl Joins Pacific Software Inc. as Chief Science Advisor	CI
06/05/24	Pacific Software, Inc. acquired Certain assets of Dreamaderm Inc. from Dreamaderm Inc.	CI
25/01/21	Pacific Software, Inc. Reports Earnings Results for the Full Year Ended September 30, 2020	CI
16/12/20	Pacific Software, Inc. Reports Earnings Results for the Full Year Ended September 30, 2019	CI
16/12/20	Pacific Software, Inc. Reports Earnings Results for the Second Quarter Ended March 31, 2020	CI
19/06/19	Pacific Software, Inc. Reports Earnings Results for the Full Year Ended September 30, 2018	CI
06/06/19	Pacific Software Inc. Enters into Memorandum of Understanding with Império Assessoria em Informaçoes LTDA	CI
13/05/19	Pacific Software, Inc. completed the spin-off of Hypersoft Ventures.	CI

01-19	Pacific Software, Inc. Announces Completion of Change of Control with PurMinds Holdings Inc.; Confirms Occupancy of a GMP Production Facility; and OTCQX Uplisting Strategy	PR
11-11	Pacific Software Inc Announces Exclusive Partnership with SpectroChip Global	PR
27/08/25	Pacific Software Inc Acquires 10763942 Canada, Inc. from PurMinds Holdings Inc., Including its PurMinds Products and Research Partners	AQ
23/07/24	Professor Dr. Robert Schiestl Ph. D. Joins Pacific Software Inc. as Chief Science Advisor (CSA)	GL
29/06/24	Pacific Software Inc. Obtaining Quotes for the Manufacturing Cycle for Scientifically Tested Medical Food Cocktail Focused on Memory Health	GL

Manager	Title	Age	Since
Janet Qi CEO	Chief Executive Officer	-	-
Angelo Pizzuto DFI	Director of Finance/CFO	-	10/06/2026

Pacific Software Inc Stock Other OTC

Stocks

US69482P1066

Biotechnology & Medical Research

Valuation : Pacific Software Inc

Latest news : Pacific Software Inc

Press Releases : Pacific Software Inc

Managers and Directors : Pacific Software Inc

Other Biotechnology & Medical Research

Financials

Company Profile

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
LONZA GROUP AG	-0.49%	-6.28%	-4.80%	+9.11%	46.05B
REVOLUTION MEDICINES, INC.	-0.08%	-3.00%	+340.58%	+519.79%	43.59B
IQVIA HOLDINGS INC.	+0.30%	-3.34%	+35.73%	+20.20%	42.35B
BEONE MEDICINES AG	+1.26%	-3.69%	+2.80%	+64.91%	38.86B
CELLTRION, INC.	-1.26%	-3.37%	+11.87%	+40.55%	32.24B
ASCENDIS PHARMA A/S	+0.36%	-3.28%	-	-	17.16B
MEDPACE HOLDINGS, INC.	+1.41%	+0.09%	+18.93%	+111.85%	16.28B
EUROFINS SCIENTIFIC SE	+0.62%	-1.87%	+11.50%	+31.71%	14.32B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.	+1.43%	-3.79%	+73.77%	+39.03%	13.03B
Average	+0.39%	-4.70%	+61.30%	+104.64%	29.32B
Weighted average by Cap.	+0.19%	-5.04%	+73.21%	+123.80%

	2019	2020
Net sales	-	0.02 0.02 0.02 0.01 0.03 1.91 0.03 0.19 0.07 0.97 0.08 0.07 3.08
Net income	-21.11M -18.16M -17.13M -15.61M -29.17M -2.02B -29.44M -204M -78.52M -1.02B -79.28M -77.55M -3.25B	-1.17M -1.01M -953K -868K -1.62M -112M -1.64M -11.35M -4.37M -56.95M -4.41M -4.31M -181M
Net Debt	-101K -86.48K -81.59K -74.33K -139K -9.61M -140K -972K -374K -4.88M -378K -369K -15.49M	367K 316K 298K 272K 508K 35.13M 512K 3.55M 1.37M 17.82M 1.38M 1.35M 56.6M

End-of-day quote Other OTC
- ^USD	-